{"entity":{"id":"jbr-10","kind":"trial","name":"JBR.10 (NCIC CTG)","aka":["NCIC CTG JBR.10","JBR10"],"tldr":"Showed that four cycles of cisplatin and vinorelbine after surgery for stage IB or II lung cancer lengthen life, and defined the regimen that became standard.","summary":"JBR.10 randomised 482 patients with completely resected stage IB or II non-small-cell lung cancer and an ECOG performance status of 0 or 1 to vinorelbine plus cisplatin (242 patients) or observation (240). Forty-five percent had stage IB disease and 55 percent stage II; the median age was 61 and 53 percent had adenocarcinoma.\n\nAdjuvant chemotherapy prolonged both disease-free and overall survival. The cost was real: neutropenia in 88 percent, including grade 3 febrile neutropenia in 7 percent, two deaths from toxic effects (0.8 percent), fatigue in 81 percent, nausea in 80 percent, anorexia in 55 percent and neuropathy in 48 percent, though severe non-haematological effects were uncommon.\n\nJBR.10 is why cisplatin with vinorelbine, rather than cisplatin with etoposide, became the adjuvant backbone, and its long-term follow-up showed the benefit was confined to stage II disease, which is why stage IB is now a discussion rather than a recommendation.","status":"positive","asOf":"2026-09-25","links":[{"label":"JBR.10 (New England Journal of Medicine 2005)","url":"https://doi.org/10.1056/NEJMoa043623"}],"tags":[],"related":[],"cancers":["resectable-nsclc"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["vinorelbine","cisplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["ialt","anita","lace-pooled-analysis"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"phase":"3","setting":"Completely resected stage IB or II non-small-cell lung cancer: four cycles of vinorelbine with cisplatin versus observation, with overall survival as the primary endpoint","sponsor":"National Cancer Institute of Canada Clinical Trials Group","result":"Adjuvant vinorelbine and cisplatin prolonged disease-free and overall survival in completely resected stage IB to II disease; grade 3-4 neutropenia in 88 percent.","yearReported":2005,"enrolled":482,"enrolledBasis":"randomised","enrolledNote":"482 patients were randomised; the trial predates routine registry reporting, so there is no ClinicalTrials.gov enrolment figure quoted here.","outcomes":[],"replication":"ANITA reproduced the result in stage IB to IIIA disease; the LACE pooled analysis confirmed a 5.4 percent absolute five-year survival benefit overall."},"route":"/trials/jbr-10/","neighbours":{"cancer":[{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"vinorelbine","kind":"drug","name":"Vinorelbine","route":"/drugs/vinorelbine/"}],"trial":[{"id":"anita","kind":"trial","name":"ANITA (Adjuvant Navelbine International Trialist Association)","route":"/trials/anita/"},{"id":"ialt","kind":"trial","name":"IALT (International Adjuvant Lung Cancer Trial)","route":"/trials/ialt/"},{"id":"lace-pooled-analysis","kind":"trial","name":"LACE (Lung Adjuvant Cisplatin Evaluation) pooled analysis","route":"/trials/lace-pooled-analysis/"}]}}